Literature DB >> 24378327

Impact of in situ granulation and temperature quenching on crystal habit and micromeritic properties of ibuprofen-cationic dextran conjugate crystanules.

Amos Olusegun Abioye1, Adeola Kola-Mustapha2, Ketan Ruparelia2.   

Abstract

Ibuprofen was recrystallized in the presence of aqueous solution of cationic dextran derivative, Diethylaminoethyl Dextran (Ddex) using the melt-in situ granulation-crystallization technique in order to produce a stable amorphous ibuprofen-Ddex conjugates with improved morphological, micromeritic and thermo-analytical characteristics without the use of organic solvent. Ddex was used in this study because of its ability to form conjugates with various drug molecules and enhance their physicochemical characteristics and therapeutic activities. Cationic dextrans are also biocompatible and biodegradable. Mechanism of conjugation as well as the impact of conjugation on the ibuprofen crystal habit was investigated. Gaussian type normal particle size distribution was obtained and the size of the crystals in the crystanule conjugates decreased steadily, with increasing concentration of Ddex, to a minimum of 480 nm (440-folds reduction, p<0.05, n=20) at Ddex molar concentration of 0.01 mM. FT-IR spectra showed electrostatic interaction and hydrogen bonding between ibuprofen and Ddex which was confirmed with the (1)H NMR and (13)C NMR spectra. DSC curves exhibited single peaks from the binary ibuprofen-Ddex conjugate crystanules suggesting compatibility and formation of an eutectic product. The conjugate crystanules showed broad and diffuse endothermic peaks with a glass transition temperature (T(g)) of 58.3 and 59.14°C at Ddex molar concentrations of 1.56 × 10(-4) and 3.125 × 10(-4)mM respectively confirming the existence of ibuprofen-Ddex crystanule conjugates in amorphous state. Higher concentrations of Ddex decreased T(g) steadily. TGA curves showed first order degradation at low molar concentrations of Ddex up to 3.125 × 10(-4)mM which coincides with the critical granular concentration of the crystanules while higher concentrations exhibited second order degradation profile. This study provides the basis for the development of stable amorphous drug-polymer conjugates with potential practical application in controlled and extended drug release formulations.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Crystal habit; Crystanules; Ibuprofen–Diethylaminoethyl Dextran conjugates; In situ granulation-crystallization; Micromeritics; Temperature quenching

Mesh:

Substances:

Year:  2013        PMID: 24378327     DOI: 10.1016/j.ijpharm.2013.12.043

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Controlled Electrostatic Self-Assembly of Ibuprofen-Cationic Dextran Nanoconjugates Prepared by low Energy Green Process - a Novel Delivery Tool for Poorly Soluble Drugs.

Authors:  Amos Olusegun Abioye; Adeola Kola-Mustapha
Journal:  Pharm Res       Date:  2014-12-20       Impact factor: 4.200

2.  Thermodynamic Changes Induced by Intermolecular Interaction Between Ibuprofen and Chitosan: Effect on Crystal Habit, Solubility and In Vitro Release Kinetics of Ibuprofen.

Authors:  Amos Olusegun Abioye; Rachel Armitage; Adeola Tawakalitu Kola-Mustapha
Journal:  Pharm Res       Date:  2015-09-24       Impact factor: 4.200

3.  Preventing Crystal Agglomeration of Pharmaceutical Crystals Using Temperature Cycling and a Novel Membrane Crystallization Procedure for Seed Crystal Generation.

Authors:  Elena Simone; Rahimah Othman; Goran T Vladisavljević; Zoltan K Nagy
Journal:  Pharmaceutics       Date:  2018-01-24       Impact factor: 6.321

4.  Ibuprofen-Loaded Chitosan-Lipid Nanoconjugate Hydrogel with Gum Arabic: Green Synthesis, Characterisation, In Vitro Kinetics Mechanistic Release Study and PGE2 Production Test.

Authors:  Syed Mahmood; Samah Hamed Almurisi; Khater Al-Japairai; Ayah Rebhi Hilles; Walla Alelwani; Azzah M Bannunah; Farhan Alshammari; Fawaz Alheibshy
Journal:  Gels       Date:  2021-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.